Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
99
resultados
Última actualización
01/06/2025 [07:15:00]
Resultados 50 a 75 de 99
Resumen de: CN119684445A
The invention relates to the technical field of biological detection, in particular to a Brucella lipopolysaccharide-resistant monoclonal antibody with a competitive effect and application of the Brucella lipopolysaccharide-resistant monoclonal antibody. The monoclonal antibody can be subjected to specific reaction with Brucella melitensis, Brucella bovis and Brucella suis, and is not subjected to specific reaction with Escherichia coli, salmonella and Yersinia enterocolitica. The positive serum of the Brucella antibody of cattle and sheep has an inhibiting effect on the combination of the monoclonal antibody and Brucella lipopolysaccharide, and can be used for establishing a Brucella antibody competitive ELISA (enzyme-linked immuno sorbent assay) detection method. The monoclonal antibody for resisting brucella lipopolysaccharide and the application of the monoclonal antibody provide solid material and technical support for the development of the detection technology of brucellosis in China.
Resumen de: CN119685198A
The invention discloses a culture medium for realizing selective enrichment of salmonella. The culture medium is prepared from a tryptone soybean broth culture medium, sodium citrate, deoxysodium cholate, distilled water and a 0.1% brilliant green aqueous solution. The invention also discloses a preparation method of the culture medium for realizing selective enrichment of salmonella, which comprises the following steps: S1, adding 30.0 g of tryptone soybean broth culture medium, 4.0 g of sodium citrate and 0.7 g of deoxysodium cholate in proportion, adding 1000mL of distilled water, heating and stirring in water bath until dissolving, sterilizing at 121 DEG C under high pressure for 15 minutes to obtain a semi-finished culture medium solution, and storing at normal temperature; and step S2, in a temporary use stage, aseptically adding 0.4 mL of 0.1% brilliant green aqueous solution into every 1000mL of semi-finished culture medium solution in a super clean bench environment, so as to prepare the culture medium for realizing selective enrichment of salmonella. The detection efficiency of pathogenic bacteria is effectively improved.
Resumen de: CN119685325A
The invention discloses a preparation method of a triangular multivalent aptamer initiation chain with magnetic nanoparticles, and particularly relates to the field of salmonella detection.The method comprises the steps that all DNA sequences are dissolved with a 1 * TMS buffer solution, and the final concentration is 50 mu M; the method comprises the following steps: adding Apt1, Apt2, Tri, Linker and an initiation chain into a 1 * TMS buffer solution to obtain a mixed solution; heating the mixed solution to 95 DEG C to react for 4 minutes, then quickly cooling to 4 DEG C, and keeping the solution at 4 DEG C for 1 minute to prepare a multivalent aptamer initiation chain crude product in a triangular structure state; carrying out ultrafiltration on the multivalent aptamer initiation chain crude product to remove free chains, so as to obtain a multivalent aptamer initiation chain marked as Tri-MAI; and washing the streptavidin-coupled nano magnetic beads with PBS (Phosphate Buffer Solution), then carrying out resuspension in a Tri-MAI solution, and incubating at room temperature for 0.5 h to obtain a triangular multivalent aptamer initiation chain with magnetic nanoparticles, which is recorded as MTAI. When the triangular multivalent aptamer initiation chain is used for detecting salmonella in a sample, the triangular multivalent aptamer initiation chain has the advantages of sensitivity, rapidness and simplicity.
Resumen de: CN119661651A
The invention discloses an antibacterial peptide CR19 and application thereof, and the amino acid sequence of the antibacterial peptide CR19 is shown as SEQ ID NO.1. The antibacterial peptide disclosed by the invention is strong in antibacterial ability, and can play a role in inhibiting bacteria at a relatively small concentration. In addition, the antibacterial peptide provided by the invention is not influenced by the drug resistance of salmonella, has an obvious inhibition effect on salmonella, and can effectively prevent and control salmonellosis. The antibacterial peptide disclosed by the invention is prepared into an antibacterial drug, a feed additive or a feeding material, and has important significance on healthy development of livestock and poultry breeding industry.
Resumen de: CN119667144A
The invention discloses an immunodetection kit based on a bimetal nano-bomb biological probe, and relates to the technical field of gene detection, the immunodetection kit comprises a test strip and an immunoprobe, the immunoprobe is a suspension of a bimetal nano-bomb and a monoclonal antibody, and the mixing ratio of the bimetal nano-bomb to the monoclonal antibody is 0.1-0.3 mg: 5 mu g. The bimetal nano-bomb has a symmetrical hollow nano-bomb structure, so that the bimetal nano-bomb has excellent colorimetric and photo-thermal properties, and the detection sensitivity of salmonella typhimurium is greatly improved.
Resumen de: CN119662868A
The invention discloses a digital PCR (Polymerase Chain Reaction) kit for detecting six pathogenic microorganisms in a water body, and belongs to the technical field of detection of the pathogenic microorganisms in the water body. The invention designs a primer pair and a probe capable of simultaneously detecting six key pathogenic microorganisms including escherichia coli, salmonella, shigella, vibrio cholerae, campylobacter jejuni and enterovirus EV71; and a nucleic acid extraction reagent and a detection reagent are prepared for the components in the kit. The kit disclosed by the invention can be used for simultaneously extracting, purifying and enriching microorganisms and free nucleic acids in various liquid samples, the samples do not need to be centrifuged or filtered and enriched, the operation is convenient, rapid detection can be realized, and the kit has high precision and sensitivity and has important significance on reducing diseases caused by biological pollution of a water environment.
Resumen de: CN119662448A
The invention discloses lactobacillus mucilaginosus and application thereof in fermentation of sporoderm-broken ganoderma lucidum spore powder. The preservation number of the lactobacillus mucilaginosus is CGMCC (China General Microbiological Culture Collection Center) No.31453. The strain is separated and screened from vaginal secretions of healthy women at the childbearing age, is not hemolyzed, is sensitive to various common antibiotics and has strong lactic acid production capacity, and fermented supernate of the strain has strong growth inhibition capacity on escherichia coli, pseudomonas aeruginosa, staphylococcus aureus, salmonella typhimurium, shigella dysenteriae and gardnerella vaginalis and can be used for producing lactic acid. The compound has strong adhesion ability, growth inhibition ability and apoptosis promoting effect on human cervical cancer cells. When the strain is used for fermenting wall-broken ganoderma lucidum spore powder, the content of bioactive substances such as amino acids and derivatives thereof, fatty acids and steroids in fermentation liquor can be greatly increased, the strain has an obvious anti-inflammatory effect on DSS-induced mouse colitis, and the inflammatory factor level is remarkably reduced. The strain not only has significant application value in functional food and biological agents, but also opens up a new way for further development of ganoderma spores.
Resumen de: CN119662505A
The invention discloses a salmonella choleraesuis three-gene deletion strain without a resistance marker, wherein the preservation number of the salmonella choleraesuis three-gene deletion strain is CCTCC (China Center For Type Culture Collection) M 20242059. The strain successively lacks a virulence regulating gene crp, an important nutrition metabolism gene asd for mediating diaminopimelic acid (DAP) synthesis, and an important carbon metabolism gene manA for mediating and coding mannose-6-phosphate isomerase. The salmonella choleraesuis gene deletion mutant strain is constructed by adopting a suicide vector and SacB reverse inheritance, and a non-resistant three-gene deletion mutant strain is obtained. The three-gene deletion mutant strain is clear in genetic background, free of resistance markers, good in safety and immunoprotectiveness to mice and capable of helping the mice to resist attack of high-lethal-dose salmonella choleraesuis, as the asd gene in the deletion strain is completely deleted in a traceless mode, a balanced lethal system plasmid pya3493-ApxIAN is electrically transformed into the deletion strain, and therefore the expression of the salmonella choleraesuis in the high-lethal-dose salmonella choleraesuis in the high-lethal-dose salmonella choleraesuis. The recombinant strain not only can grow in a DAP-free culture medium, but also can stably express foreign protein ApxIAN, and has a wide application prospect.
Resumen de: CN119656167A
The invention discloses an application of 2-aminoquinoline in preparation of drugs for inhibiting salmonella typhimurium. 2-aminoquinoline is combined with LsrB protein to inhibit expression of QS-related genes and virulence genes and inhibit formation of a biofilm, so that the pathogenicity of salmonella typhimurium is reduced, and the application of 2-aminoquinoline in preparation of drugs for inhibiting salmonella typhimurium is realized. And the 2-aminoquinoline can inhibit invasion and adhesion of salmonella typhimurium to cells, so that the 2-aminoquinoline can be applied to preparation of salmonella typhimurium inhibiting drugs.
Resumen de: CN119661677A
The invention provides a scophthalmus maximus-derived antibacterial peptide SMGAP. The amino acid sequence of the scophthalmus maximus-derived antibacterial peptide SMGAP is as shown in SEQ ID NO: 1. The invention provides a scophthalmus maximus-derived fused antibacterial peptide. The amino acid sequence of the scophthalmus maximus-derived fused antibacterial peptide is as shown in SEQ ID NO: 2. The invention provides application of the scophthalmus maximus-derived antibacterial peptide SMGAP or the fusion type antibacterial peptide in preparation of an antibacterial product, and in the antibacterial product, the antibacterial peptide SMGAP or the fusion type antibacterial peptide is an active component. The antibacterial peptide SMGAP disclosed by the invention has an obvious effect of inhibiting the growth of Edwardsiella piscicida EIB202, Salmonella Typhimurium SL1344, and Escherichia coli O157: H7EDL933, and the antibacterial peptide SMGAP disclosed by the invention has an obvious effect of inhibiting the growth of the Edwardsiella piscicida EIB202, the Salmonella Typhimurium SL1344 and the Escherichia coli O157: H7EDL933.
Resumen de: CN119661391A
The invention relates to the technical field of compound eutectic crystals, and discloses an L-lysine and plant essential oil active component eutectic crystal and a preparation method and application thereof. The eutectic crystal is prepared from the following raw materials: L-lysine and plant essential oil active ingredients, the molar ratio of the L-lysine to the active ingredients of the plant essential oil is 1: 1; the active ingredient of the plant essential oil is at least one of eugenol and cinnamyl aldehyde. The eutectic crystal provided by the invention is formed by at least one of eugenol and cinnamyl aldehyde and L-lysine, is low in hygroscopicity and volatility and good in stability, and overcomes the defects that single L-lysine is strong in hygroscopicity and inconvenient to process and store, and single eugenol or cinnamyl aldehyde is strong in volatility and poor in stability; compared with single eugenol or cinnamyl aldehyde, the eugenol/cinnamyl aldehyde co-crystal shows lower minimum inhibitory concentration on various bacteria such as escherichia coli, staphylococcus aureus, salmonella enteritidis, candida albicans, nigmycin, aspergillus flavus and the like, and has a good antibacterial effect.
Resumen de: CN119662557A
The invention relates to the technical field of microorganisms, in particular to a multi-drug-resistant salmonella virulent phage and application thereof. The phage is named as vB-Sal-TmvP009 and is sent to the general microbiological center of the China Committee for Culture Collection of Microorganisms, the preservation number is CGMCC No.46177, and the preservation date is September 2, 2024. The bacteriophage provided by the invention is separated from sewage of a livestock farm, belongs to a tailed virus, and is expressed by genomics, belongs to Jerseyvirus, has no virulence gene and no drug-resistant gene, and is high in safety. The biological characteristic result of the bacteriophage shows that at least 10 salmonella serotypes can be split, the temperature (-20 DEG C to 60 DEG C) stability and the acid-base (pH = 3-12) stability of the bacteriophage are good, the average splitting quantity reaches 9.77 * 10 < 4 >, and the bacteriophage can be massively proliferated in a short time and can be used for preventing and controlling drug-resistant salmonella.
Resumen de: CN119662858A
The invention relates to a primer and probe combination, a kit and a method for detecting gastrointestinal tract pathogenic bacteria. The gastrointestinal pathogenic bacteria comprise vibrio cholerae, vibrio parahaemolyticus, salmonella, shigella, diarrheagenic escherichia coli, campylobacter, yersinia enterocolons, clostridium difficile, cronobacter sakazakii, aeromonas hydrophila, plesiomonas shigelloides and vibrio fluvialis. The primer and the probe group can be independently used for PCR amplification detection and can be combined in the same reaction system and reaction procedure for multiple PCR amplification detection, and the primers and the probes aiming at different pathogenic bacteria cannot interfere with each other during multiple PCR amplification detection. The primer and probe combination covers various types of gastrointestinal pathogenic bacteria, and is high in sensitivity, low in detection limit, good in specificity and wide in application prospect.
Resumen de: US2025092355A1
The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, and engineered host cells for producing fatty acids and derivates of fatty acids such as acyl-CoA, terminal olefins, fatty aldehydes, fatty alcohols, alkanes, alkenes, wax esters, ketones and internal olefins through altered expression of the transcription factor, fadR.
Resumen de: AU2022480516A1
Provided is a method against Salmonella typhimurium infection using a composition containing cultures of Lactobacillus rhamnosus LRH10 which is deposited at the Deutsche Sammlung Von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 32786, Lactobacillus paracasei LPC12 which is deposited at the DSMZ GmbH under an accession number DSM 32785, Lactobacillus fermentum LF26 which is deposited at the DSMZ GmbH under an accession number DSM 32784，Streptococcus thermophilus ST30 which is deposited at the DSMZ GmbH under an accession number DSM 32788, and Lactobacillus helveticus LH43 which is deposited at the DSMZ GmbH under an accession number DSM 32787.
Resumen de: AU2023338191A1
The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live
Resumen de: US2025093348A1
A nucleic acid testing device and method are provided. A base plate that is turned during nucleic acid testing is included, wherein the base plate includes the following chambers: a sample chamber for adding and containing a nucleic acid sample solution, the nucleic acid sample solution is placed in the chamber, and an upper port of the sample chamber communicates with the outside atmosphere; a reaction chamber for nucleic acid amplification reaction and located below the sample chamber, a nucleic acid amplification reagent for nucleic acid amplification reaction is pre-placed in the chamber, and an upper end of the reaction chamber communicates with a bottom end of the sample chamber though a longitudinal liquid channel; a test strip chamber for lateral flow test strip testing, a nucleic acid test strip is pre-placed in the chamber, and the test strip chamber communicates with the reaction chamber through a bent channel.
Resumen de: CN119638796A
The invention relates to the technical field of agriculture, animal husbandry and veterinary medicine, in particular to a protease cracking resistant antibacterial peptide FR and application thereof. The invention provides a protease cracking resistant antibacterial peptide FR. The amino acid sequence of the antibacterial peptide FR is as shown in SEQ ID NO. 1. The specific implementation result shows that the protease cracking resistant antibacterial peptide FR provided by the invention has the activity of resisting gram-negative bacteria (escherichia coli, shigella flexneri, salmonella, campylobacter jejuni and the like), also has low hemolytic activity, can resist cracking of high-concentration protease, and has a very good application prospect. In conclusion, the antibacterial peptide FR provided by the invention has the advantages of gastrointestinal tract environment resistance, high salt resistance and protease lysis resistance, can realize the killing effect on gram-negative bacteria in the presence of enzymes and salt ions, has the characteristic of low hemolytic activity, and provides a new way for development of antibiotic substitutes.
Resumen de: CN119633101A
本发明公开了SseB蛋白在制备交叉免疫同源或异源血清型肠炎沙门菌的疫苗中的应用。本发明使用动物实验评估其免疫保护力，结果发现肠炎沙门菌SseB蛋白具有良好的免疫反应性，可以显著减轻肠炎沙门菌同源或异源血清型野生菌株引起的临床症状。本发明涉及的具有交叉免疫保护作用的肠炎沙门菌SseB蛋白，具有作为研制肠炎沙门菌亚单位疫苗的潜力。
Resumen de: CN119639685A
The invention discloses two split wide-spectrum bacteriophages, different bacteriophage combinations and application thereof, and belongs to the field of microorganisms. The two bacteriophages are preserved in the China Center for Type Culture Collection (CCTCC), and the preservation numbers of the two bacteriophages are respectively CCTCC M 20242502 and CCTCC M 20242503. The bacteriophage provided by the invention can kill various pathogenic bacteria including salmonella paratyphi, salmonella typhimurium, salmonella enteritidis, salmonella salmonella duck, salmonella choleraei, shigella and escherichia coli in a cross-genus manner, has relatively high temperature tolerance and a relatively wide acid-base tolerance range, and is beneficial to industrial production; the bacteriophage combination can resist generation of resistant bacteria on the basis of wide-spectrum bacteriostasis, and a more lasting and effective bacteriostasis effect is achieved. The two bacteriophages and the bacteriophage combination have excellent capabilities of cracking, preventing, controlling and detecting various pathogenic bacteria.
Resumen de: CN119632962A
The invention belongs to the technical field of biological medicine, and discloses application of isoliquiritigenin as a polymyxin synergist. Through combination of isoliquiritigenin and polymyxin, it is found that isoliquiritigenin and polymyxin have a good effect on in-vivo and in-vitro salmonella inhibition. The isoliquiritigenin is safe in component, can achieve a good synergistic effect with the polymyxin, can significantly reduce the dosage of the polymyxin, is not easy to induce the generation of bacterial drug resistance, and has the characteristics of low price and good curative effect.
Resumen de: CN119632986A
The invention provides medical application of sanguinarine in preparation of a salmonella flagellum inhibitor, and belongs to the technical field of biological medicine. According to the invention, the flagellum of salmonella is used as a potential target for researching and developing the anti-salmonella toxicity drug, and a natural product capable of inhibiting the flagellum of salmonella is screened through a salmonella sliding motion inhibition test and a real-time fluorescent quantitative PCR test; in combination with tests such as a minimum inhibitory concentration determination test, a growth curve, inhibition of salmonella from adhesion to Caco-2 cells and the like, it is verified that sanguinarine can effectively inhibit the salmonella flagellum-mediated swimming ability on the basis of not influencing normal growth of bacteria, so that the pathogenic potential of salmonella is remarkably reduced, the effect of bacteriostasis instead of sterilization is achieved, and the application prospect is broad. A new research thought and a candidate natural compound are provided for prevention and treatment of salmonella infection, and potential practical application value is achieved.
Resumen de: CN119633098A
The invention belongs to the technical field of biological medicines, and discloses a composition of a thiazolidinyl urea compound and polymyxin and application of the composition to preparation of salmonella infection resisting medicines. According to a sterilization curve obtained after the thiazolidinyl urea compound and the polymyxin are combined for use, the 24-hour bacterium loading amount is reduced by more than 100 times compared with that of a single drug, and a good synergistic sterilization effect is shown when the thiazolidinyl urea compound and the polymyxin are combined for use. The thiazolidinyl urea compound is simple in source and synthesis, the dosage of polymyxin can be remarkably reduced, the possibility that the polymyxin generates drug resistance is reduced under the condition that a better sterilizing effect is achieved, and the thiazolidinyl urea compound has a better prospect in application of the polymyxin combined drug to the salmonella infection resisting drug.
Resumen de: CN119633099A
The invention belongs to the technical field of bacterial infection and drug treatment, and discloses an ability of oridonin in combined synergism of anti-salmonella effect of polymyxin. The invention verifies that oridonin and polymyxin are combined to resist salmonella in a macrophage intracellular environment simulation culture medium that oridonin has a remarkable synergistic capability on the salmonella inhibition capability of polymyxin; a growth curve experiment and a combined sterilization curve experiment verify that oridonin enhances the salmonella infection resistance of polymyxin. A novel combined method and a research and development strategy are provided for clinically treating salmonella infection by polymyxin. Compared with a traditional action mechanism that antibiotics directly kill salmonella, oridonin inhibits salmonella infection by effectively enhancing the sterilization effect of polymyxin, bacterial infection can be effectively prevented and treated while the application concentration of polymyxin can be reduced, and salmonella is not prone to being induced to generate related drug resistance.
Nº publicación: CN119639929A 18/03/2025
Solicitante:
ZHEJIANG YUZHI BIOTECHNOLOGY CO LTD
\u6D59\u6C5F\u4E88\u667A\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
Resumen de: CN119639929A
The invention belongs to the field of biology, relates to a salmonella gene detection technology, and discloses a one-pot detection method combining LAMP (loop-mediated isothermal amplification) and CRISPR/BrCas12b mediated nucleic acid molecule detection. The method comprises the following steps: designing an LAMP primer, a small guide RNA (Ribonucleic Acid) and a transcription template overlapping PCR (Polymerase Chain Reaction) primer, performing loop-mediated isothermal amplification, constructing CRISPR/Cas shearing recognition (Cas-LAMP), constructing a single-tube one-pot reaction system of the CRISPR/Cas shearing recognition, detecting the specificity and sensitivity of Cas-LAMP amplification, and the like. In order to solve the technical problem that amplification and shearing recognition cannot be carried out synchronously, the invention provides a Cas-LAMP technology capable of linking two-step reaction of amplification and shearing recognition, and accurate, sensitive and rapid detection of nucleic acid molecules is realized in an in-vitro single reaction tube system. Compared with a traditional nucleic acid molecule detection method, the method has the following advantages that one-pot detection can be directly carried out without step-by-step operation, high sensitivity and strong specificity are achieved, and rapid field detection can be achieved. The method provides technical support for conventional nucleic acid detection, and has a wide field instant detecti
BOPI
Sede Electrónica
